Connect with us

News

Mundipharma Welcomes the New 2020 Clinical Practice Guideline from KDIGO recommending SGLT2is alongside metformin as first-line anti-hyperglycaemic therapy in type 2 diabetes patients with chronic kidney disease

gbafNews28

As the European distributor of Invokana (canagliflozin) and Vokanamet (canagliflozin and metformin), Mundipharma welcomes the publication of the first KDIGO (Kidney Disease: Improving Global Outcomes) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD). The new guideline recommends the use of sodium-glucose co-transporter-2 inhibitor (SGLT2i) class, which includes canagliflozin, as a first-line treatment option alongside metformin for the management of hyperglycaemia in patients with type 2 diabetes mellitus (T2DM), CKD and eGFR ‰¥30 ml/min/1.73 m2.1

This new guideline includes data from CV outcomes trials (CVOTs) for SGLT2is which give evidence of significant cardioprotective and possible kidney-protective effects across the class. This includes the positive CV outcomes data for canagliflozin,2 empagliflozin and dapagliflozin, and CKD outcomes from the canagliflozin CREDENCE clinical trial.3 The guideline also highlights that whilst kidney events were secondary outcomes in most of the CVOTs, CREDENCE was the first randomised controlled trial specifically powered for primary renal outcomes among patients exclusively with albuminuric CKD.3

The CREDENCE trial is the first dedicated renal outcomes study in patients with DKD and T2DM. The study enrolled 4401 subjects with an eGFR of 30 to <90ml/min/1.73m2 and albuminuria (urinary albumin: creatinine ratio >300 to 5000 mg/g). Importantly, all patients were treated on a background of standard of care for DKD, including a maximum tolerated dose of an ACE inhibitor or ARB. The results showed that canagliflozin demonstrated a 30% reduction, compared to placebo, in the risk of the primary composite endpoint, comprising end-stage renal disease (ESRD), doubling of serum creatinine and renal or cardiovascular (CV) death, with event rates of 43.2 vs 61.2 per 1000 patient years, respectively (Hazard Ratio [HR]: 0.70; 95% Confidence Interval [CI]: 0.57 to 0.84; p<0.0001).5

Canagliflozin received approval from the European Commission (EC) in July this year, to extend its treatment of T2DM indication in Europe to treat diabetic kidney disease (DKD) in T2DM patients.6 It is currently the only SGLT2i labelled to treat DKD in TD2M patients.

The KDIGO recommendations are based on evidence from recent clinical trials. These trials include CREDENCE, which demonstrated that canaglifozin reduced the risk of deteriorating kidney function and associated cardiovascular complications in patients with both type 2 diabetes and chronic kidney disease. CREDENCE is one reason why SGLT2 inhibitors have been given a prime position in diabetes management in the guideline, said Professor David Wheeler, Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free NHS Foundation Trust, London, UK.

An estimated 59 million adults in Europe currently live with diabetes and around 90% of these have T2DM. This figure is set to rise to 68 million by 2045.7 If left untreated, people with T2DM are at greater risk of developing serious health complications, such as CKD, heart failure (HF), and CV disease, which is the most common cause of death amongst them.8 It is estimated that approximately 40% of people with T2DM will go on to develop CKD,4 so effective therapies need to be sought rapidly to halt the progression of the disease.1

People with type 2 diabetes and chronic kidney disease are at greater risk of cardiovascular disease and progression to end-stage kidney disease, so it is of paramount importance that physicians have clear guidelines which recommend appropriate therapies to help prevent these risks, said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma.

The KDIGO guideline can be viewed at: https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-in-CKD-GL.pdf.

-END-

Notes to the editors:

About the KDIGO Guideline1 The first KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease was published in https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-in-CKD-GL.pdf.

About Invokana (canagliflozin) Canagliflozin is an oral, once-daily medication that belongs to a class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors work by inhibiting SGLT2 co-transporter, which promotes the excretion of glucose via the urine, and thus helps lowering blood glucose levels in adults with T2DM.5

Canagliflozin was approved in the European Union by the European Commission in November 2013. It is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contra-indications and in addition to other medicinal products for the treatment of diabetes.5

The recommended initiation dose of canagliflozin is 100 mg once daily in adults with an eGFR of ‰¥ 60 mL/min/1.73 m2 and can be increased to 300 mg once daily if tighter glycaemic control is needed. For patients with an eGFR of 45 to <60 mL/min/1.73 m2 the initiation dose is limited to 100mg once daily, if further glycaemic control is needed the addition of other anti-hyperglycaemic agents should be considered. In patients with an eGFR of 30 to < 45 mL/min/1.73 m2 with a urinary albumin/creatinine ratio ˃ 300 mg/g, the initiation dose is limited to 100 mg once daily, if further glycaemic control is needed the addition of other anti-hyperglycaemic agents should be considered. Canagliflozin should not be initiated if eGFR is below 30 mL/min/1.73 m2, but for patients already taking canagliflozin it should be continued at 100 mg until dialysis or renal transplantation is required.5

Approval was based on a comprehensive global Phase III clinical trial programme.

About the CANVAS Programme2 The CANVAS Programme (N=10,142) comprised the two large canagliflozin cardiovascular outcome trials, CANVAS and CANVAS-R, and included a pre-specified integrated analysis of these two studies to evaluate the potential for CV protection of canagliflozin in patients with T2DM who had either a prior history of CV disease or at least two CV risk factors. The integrated analysis also evaluated the effects of canagliflozin on renal and safety outcomes.

Canagliflozin met the primary outcome by significantly reducing the rates of the composite of major adverse CV events (MACE) comprised of CV mortality, non-fatal myocardial infarction (MI), or non-fatal stroke (26.9 vs. 31.5/1000 patient-years, hazard ratio (HR) 0.86; 95% confidence interval (CI 0.75-0.97; P<0.0001 for non-inferiority; P=0.0158 for superiority) compared with placebo plus standard of care, respectively. All 3 components of MACE composite (CV death, non-fatal MI, and non-fatal stroke) exhibited point estimates of effect suggesting benefit with canagliflozin.

Adverse events reported in the CANVAS Programme were generally consistent with the known safety profile of canagliflozin. Whilst an increase in lower limb amputation and bone fractures were observed in the CANVAS Programme, this signal was not observed in further long term clinical trial data involving high risk patients.3

About the CREDENCE Clinical Trial3 The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study was the first dedicated and fully recruited renal outcome trial evaluating renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) with a sodium glucose co-transporter 2 (SGLT2) inhibitor. It was a phase III randomised, double-blind, event-driven, placebo-controlled, parallel-group, two-arm multicentre study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with T2DM and CKD. In particular, it compared the efficacy and safety of canagliflozin versus placebo in preventing clinically important kidney and cardiovascular outcomes in patients with T2DM and CKD when used in addition to standard of care, including a maximum tolerated daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

About the Mundipharma network Mundipharma is a global (ex-US) network of privately-owned independent associated companies with a presence across Africa, Asia Pacific, Europe, Canada, Latin America and the Middle East.

We are dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as Anti-Infectives, Biosimilars, CNS, Diabetes, Oncology & supportive care, Ophthalmology, Pain Management, Respiratory and Consumer Healthcare.

For further information by geographic region please go to www.mundipharma.com (Europe); www.purdue.ca (Canada) and www.mundipharma.com.sg (other ex-US markets).

Invokana is a registered trademark of Johnson & Johnson. The Marketing Authorisation Holder is Janssen-Cilag International NV.

References:


1 KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. Oct 2020; 98(4S): S1“S115. Available at https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-in-CKD-GL.pdf. Last accessed September 2020.

2 Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine (2017);377:644-657.

3 Perkovic, V. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephrology. The New England Journal of Medicine. 2019; 380(24): 2295-2306.

4Alicic R, Rooney M, Tuttle K. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017; 12(12):2032-45.

5 Invokana SMPC. Updated July 2020 https://www.medicines.org.uk/emc/product/8855 Last accessed July 2020

6 European Commission. 26th June 2020 Decision C(2013)8171(final) for Invokana “ canagliflozin. Available at https://ec.europa.eu/health/documents/community-register/html/h884.htm. Last accessed July 2020.

7 IDF Diabetes Atlas Ninth Edition 2019. Available at: https://www.diabetesatlas.org/en/resources/ Last accessed July 2020

8 Einarson T, Acs A, Ludwig C. et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83.

Job code: MINT/MINVK-20034 Date of preparation: October 2020

For further information please contact:

Cendrine Banerjee-Quetel

Asset Communications Associate, Mundipharma International Ltd

Email: [email protected]

Tel: +44 (0) 1223 393 009

Abbie Bell

Account Director, Havas SO

E-mail: [email protected]

Tel: +44 7375 660 515

News

Xinhua Silk Road: China’s Putian City unveils “Credit Shoe City” brand logo globally

gbafNews28

BEIJING, Oct. 20, 2020 /PRNewswire/ — Putian City, located in southeast China’s Fujian Province, recently released the "Credit Shoe City" brand logo globally.

Putian City, located in southeast China's Fujian Province, recently released the "Credit Shoe City" brand logo globally.
Putian City, located in southeast China’s Fujian Province, recently released the "Credit Shoe City" brand logo globally.

The logo, with green innovation, environmental protection and passion as its design concept, uses the background that Putian has been selected as the second batch of social credit system construction demonstration city and conveys visually the idea that Putian footwear products boast high quality, good design, diversity and fashion.

According to the designer, the logo, highly condensed with elements such as "Putian", "Shoe City" and "Credit," is concise, unique and recognizable.

As the traditional advantage in Putian, the footwear industry employs more than 200,000 people, involving more than 3,000 upstream and downstream companies. There are 20 footwear research and development institutions, with about 10,000 technical personnel. 

An official with Putian Footwear Association said that the footwear products made in Putian are good in quality and design and fashionable. The annual output value of the industry has exceeded 100 billion yuan by far.

In order to further strengthen the development of the footwear industry, the Putian Footwear Association will guide footwear companies to build an industrial credit system, make full use of new technological means including big data and cloud computing, rely on related APP platforms such as Credit China (Putian, Fujian), Putian Huiminbao to build a "credit shoe city." 

The APP platforms Credit China (Putian, Fujian) and Putian Huiminbao display the credit information of local shoe companies and accept complaints, reports, feedback and suggestions from consumers. The public can also view and retrieve the credit scores, corporate rankings, credit ratings of local shoe companies and download corporate credit reports as well.

Original link: https://en.imsilkroad.com/p/316911.html

Continue Reading

News

OneConnect Shares Fintech Insights with Chinese Banks and Fintech Companies

gbafNews28

HONG KONG, Oct. 20, 2020 /PRNewswire/ — OneConnect Financial Technology Co., Ltd. (OneConnect, NYSE: OCFT), a leading technology-as-a-service platform for financial institutions, shared its vision of innovation with the Fintech Association of Hong Kong of the Chinese Banking Association of Hong Kong at a recent video conference.

Carol Chen, CEO of OneConnect (Hong Kong), and Daniel Ling, General Manager, discussed the company’s technical solutions for popular banking fields, such as remote customer service solutions and customer due diligence with more than 100 executives and industry experts.

As of June 30, 2020, OneConnect, an associate company of the Ping An Group, had served all state-owned banks and joint-stock banks in China, 99% of commercial banks, and 53% of insurance companies.

Ms. Chen and Mr. Ling presented end-to-end fintech solutions for banks, securities, asset management companies and other fintech institutions in mainland China and Hong Kong. These include localized fintech technology services such as smart marketing, smart risk controls, smart operations and fintech centers.

They also covered solutions implemented at Ping An OneConnect Bank, OneConnect’s virtual banking subsidiary: the process for opening a bank account online, opening an online small and medium enterprises (SME) account and loan solutions, and cloud-based core banking, which improves sales, risk management and customer service quality.

Jessica Tan, Co-CEO of Ping An Group has said that Ping An will continue to increase its investments in technology to bolster its main businesses. "Particularly in terms of fintech, OneConnect will continue to develop and invest in innovative products," she said.

Ping An uses technology to empower its main financial businesses. In the first half of 2020, Ping An achieved artificial intelligence (AI)-driven product sales of RMB176.3 billion. Its online and technology-powered offline services across the Ping An Group supported 560 million online users.

OneConnect has branches in Hong Kong, Singapore, and Indonesia and provides services to major banks in Thailand, Indonesia, Malaysia and the Philippines. As of June 30, 2020, OneConnect had provided services to or signed cooperation agreements with more than 50 overseas institutions in more than 15 countries and regions.

Continue Reading

News

Farmmi Receives NASDAQ Minimum Bid Price Requirement Extension

gbafNews28

LISHUI, China, Oct. 20, 2020 /PRNewswire/ — Farmmi, Inc. ("Farmmi" or the "Company") (NASDAQ: FAMI), an agriculture products supplier in China, today announced that on October 19, 2020, it received notification from The Nasdaq Stock Market LLC ("NASDAQ") confirming the Company has been granted an additional 180 calendar day period for compliance under its minimum bid price requirement through April 13, 2021. To regain compliance with NASDAQ’s minimum bid price requirement, the closing bid price of the Company’s ordinary shares needs to be at least $1.00 per share or greater for at least ten consecutive business days by April 13, 2021.

About Farmmi, Inc.

Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products. The Company’s Farmmi Liangpin Market serves as a trading platform for Chinese geographical indication agricultural products and is a large platform for consumers to access locally sourced agricultural products. For further information about the Company, please visit: http://ir.farmmi.com.cn/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including the potential impact of COVID-19 on our business within and outside of China.  These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

Related Links :

http://www.farmmi88.com

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News1 hour ago

TuanChe Announces ADS Ratio Change

BEIJING, Oct. 20, 2020 /PRNewswire/ — TuanChe Limited ("TuanChe" or the "Company") (NASDAQ: TC), a leading omni-channel automotive marketplace in...

gbafNews28 gbafNews28
News1 hour ago

Farmmi Receives NASDAQ Minimum Bid Price Requirement Extension

LISHUI, China, Oct. 20, 2020 /PRNewswire/ — Farmmi, Inc. ("Farmmi" or the "Company") (NASDAQ: FAMI), an agriculture products supplier in China,...

gbafNews28 gbafNews28
News1 hour ago

OneConnect Shares Fintech Insights with Chinese Banks and Fintech Companies

HONG KONG, Oct. 20, 2020 /PRNewswire/ — OneConnect Financial Technology Co., Ltd. (OneConnect, NYSE: OCFT), a leading technology-as-a-service platform for...

gbafNews28 gbafNews28
News1 hour ago

Xinhua Silk Road: China’s Putian City unveils “Credit Shoe City” brand logo globally

BEIJING, Oct. 20, 2020 /PRNewswire/ — Putian City, located in southeast China’s Fujian Province, recently released the "Credit Shoe City"...

gbafNews28 gbafNews28
News1 hour ago

Ireland’s Leading Property Developer Bartra Offers Immigration Consultancy Service in Hong Kong

HONG KONG, CHINA – Media OutReach – 20 October 2020 – Bartra Wealth Advisors (‘Bartra’), a subsidiary of Ireland’s market...

gbafNews28 gbafNews28
News3 hours ago

Yeastar to Host a Virtual Launch Event for Its Upcoming P-Series PBX System

XIAMEN, China and DALLAS, Oct. 20, 2020 /PRNewswire/ — Yeastar (www.yeastar.com), the world’s leading provider of SME PBX system, today announced...

gbafNews28 gbafNews28
News3 hours ago

Danke Releases 2020 Report on Chinese Millennial Spending Habits

BEIJING, Oct. 20, 2020 /PRNewswire/ — Phoenix Tree Holdings Limited ("Danke" or the "Company") (NYSE: DNK), one of the largest co-living...

gbafNews28 gbafNews28
News3 hours ago

Vestiaire Collective x BCG: The Consumer Behind Fashion’s Growing Secondhand Market

– The global secondhand market is predicted to grow by a CAGR of 15% to 20% – Secondhand consumption is...

gbafNews28 gbafNews28
News3 hours ago

Ping An Voted as the Best Overall Outstanding Company in China by Asiamoney

HONG KONG and SHANGHAI, Oct. 20, 2020 /PRNewswire/ — Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the...

gbafNews28 gbafNews28
News5 hours ago

Seoul to host “Seoul Global Challenge 2021” to seek for innovative solutions to improve air quality in Seoul subway; finally selected teams to receive a cash prize of 690 mil. won

– The Challenge 2021 consists of the technology competition and the academic paper competition to find “Innovative Technology to Improve...